The triple therapy Power
Now a new study has tested a combination of targeted therapies without the #chemotherapy. Researchers call this the BEACON CRC Phase III trial.
Their study appears in the Annals of Oncology and featured at the #ESMO World Congress on Gastrointestinal Cancer 2019.
A mixture of three drugs — two targeting the #cancer cells and one inhibiting the BRAF gene — was analyzed on a number of individuals who had not responded to one or two previous treatment regimes.
There were 665 participants in total. Researchers gave some all three drugs: #encorafenib, #cetuximab, and #binimetinib. Others had a double therapy of BRAF inhibitor encorafenib and cancer-treating cetuximab.
“Colorectal cancer does not respond to BRAF therapy alone because tumor cells adapt through other mechanisms after initial treatment,” explains Dr. Scott Kopetz, study author from the University of Texas MD Anderson Cancer Center in Houston.
“With this triple targeted therapy, we are using a very scientifically logical combination to inhibit BRAF and these other mechanisms.”
Longer survival and better response
The focus was on triple therapy, and this proved to be the most successful option. While standard therapy gave a general survival rate of 5.4 months, the three-drug combination provided a median survival rate of 9 months.
The response rate showed even greater improvement at 26% for the triple therapy versus just 2% for the standard regime.
The researchers did not compare the triple and double therapies, but the two-drug combination gave a general survival rate of 8.4 months.
Dr. Kopetz describes the findings as “very exciting because we’ve been trying to target BRAF-mutant colorectal cancer for many years.”
“Hopefully, this will soon lead to increased access to this treatment for patients where there is currently such a large unmet need.”
Although future studies will need to look at whether double or triple therapy is best for individuals, researchers believe that the three-drug treatment should replace chemotherapy for those with a BRAF mutation.
“The fact that we can give this targeted combination without the need for chemotherapy is very good news for patients, not least because of the side effects that they typically experience with chemotherapy,” notes study co-author and professor Andres Cervantes from the Biomedical Research Institute INCLIVA at the University of Valencia, Spain.
It is also, therefore, “essential that patients are routinely tested” for the mutation.
Prof. Cervantes adds that, for the time being, they should restrict targeted therapy to those individuals treated in the BEACON CRC trial who have progressed after one or two earlier lines of chemotherapy.
“However, it is important that we investigate its use in other settings where more patients with BRAF mutations may also benefit, including those with less advanced metastatic disease and possibly in the adjuvant setting after primary surgery with curative intent.”
-Prof. Andres Cervantes